The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.
Your search for major depressive disorder returned 137 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.
Migraine was more significantly associated with pain or muscle soreness than anxiety disorders in patients with depression.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Mirtazapine is a central alpha-2 antagonist currently FDA-approved for the treatment of major depressive disorder.
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
For patients with major depressive disorde, relapse is associated with brain cortical changes over two years.
Migraine with active headache may predict other painful physical symptoms in patients with major depressive disorder.
HIV-infected adults with major depressive disorder have a 30% increased risk for acute myocardial infarction.
Researchers suggest that improvement in cognitive function should be a goal for major depressive disorder because their data showed little improvement in the cognitive abilities of patients with major depression after treatment with psychological interventions.
The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
Serotonergic antidepressants are effective for sleep disturbances in perimenopausal and postmenopausal women even without major depressive disorder.
While the relationship between current mood state and cognitive impairment is unclear, more severe depression has been linked to greater impairment.
Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.
The degree of overlap between MDD and burnout is unclear. However, dysfunctional sleep patterns are known risk factors for both conditions.
Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.
The treatment is currently being evaluated in a Phase 2 study (ELEVATE) in patients with major depressive disorder who have had an inadequate response to standard antidepressant therapy.
There was insufficient evidence to recommend screening in children aged 11 and younger.
Effectively treating pain may help improve cognitive and functional outcomes in patients with depression.
The comorbidity of depressive disorders and late-life neurodegenerative diseases including Alzheimer disease has been widely reported. This study looks into whether there is a causal relationship existing between both or, if their co-occurrence is due to confounding or common risk factors, such as aging.
This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.
Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.
Is there a causal relationship between depressive disorders and late-life neurodegenerative diseases? Or, is their co-occurrence due to confounding or common risk factors, such as aging?
Sixty percent of patients responded to treatment.
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.